Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Pancreatic ductal adenocarcinoma (PDAC), which is the most common form of pancreatic cancer, is an aggressive disease with a poor prognosis, making it the most lethal tumor. The overall 5-year survival rate of PDAC is around 10 % despite the advances made in recent years in the field of oncology [1,2]. The only curative option for patients with this oncological condition is surgical resection of the primary tumor, although this is only feasible in a small percentage of cases when the malignancy is detected at a very ear ly stage. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 11, 2024 Category: Cancer & Oncology Authors: Elena Brozos-V ázquez, Marta Toledano-Fonseca, Nicolás Costa-Fraga, María Victoria García-Ortiz, Ángel Díaz-Lagares, Antonio Rodríguez-Ariza, Enrique Aranda, Rafael López-López Tags: Anti-tumour Treatment Source Type: research
Clinical Management, Monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Antibody –drug conjugates (ADCs) are directed therapies that are designed to increase efficacy and decrease toxicity compared with conventional chemotherapy through the selective delivery of cytotoxic agents to tumor cells [1,2]. ADCs that have been approved as anti-cancer agents in various solid tumors in clude trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), sacituzumab govitecan, mirvetuximab soravtansine, and tisotumab vedotin [3–7]. However, some patients have experienced adverse events (AEs) that require prevention, early recognition, and appropriate management [3–7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 11, 2024 Category: Cancer & Oncology Authors: Rebecca S. Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S.M. Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam Source Type: research
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms
Soft tissue sarcomas are a heterogeneous group of neoplasms with both simple and complex karyotypes, representing 0.7 % of all cancers [1]. Adipocytic neoplasms are among the most common mesenchymal tumors, with liposarcomas accounting for approximately 20 % of all soft tissue sarcomas [2]. Liposarcoma presents primarily as tumors in adults, with a peak incidence between the ages of 50 to 65; however, a small proportion of liposarcoma cases are seen in younger populations [3]. Liposarcoma can be divided into three main categories: (1) atypical lipomatous tumors or well-differentiated liposarcoma (ALT or WDLPS) and ded...
Source: Cancer Treatment Reviews - March 9, 2024 Category: Cancer & Oncology Authors: A. Kyriazoglou, A. Pagkali, I. Kotsantis, P. Economopoulou, M. Kyrkasiadou, M. Moutafi, N. Gavrielatou, M. Anastasiou, A. Boulouta, A. Pantazopoulos, M. Giannakakou, A. Digklia, A. Psyrri Tags: Systematic or Meta-analysis Studies Source Type: research
How to manage waldenstr öm’s macroglobulinemia in 2024
Waldenstr öm’s Macroglobulinemia (WM) belongs to the group of indolent B-cell lymphomas. It is seen as a clinicopathological entity characterized by the infiltration of the bone marrow by lymphoplasmacytic lymphoma, and the presence of monoclonal IgM paraprotein in the serum [1,2]. By this, this lymphoma c auses symptoms due to lymphoma infiltration, such as anemia or lymph node enlargement, well known from other nodal B-cell lymphomas e.g. follicular lymphoma, as well as symptoms due to the IgM protein causing symptoms such as neuropathy, hemolysis or hyperviscosity [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 5, 2024 Category: Cancer & Oncology Authors: Alexander Grunenberg, Christian Buske Tags: Tumour Review Source Type: research
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design
Historically, patients afflicted with cancer are treated on the basis of their histological subtype and the site of origin for their malignancy, as determined by the light microscope. However, rapid advances in the ability to interrogate cancers based on genomic/transcriptomic sequencing have yielded clinical-grade tests, almost unthinkable just a few years ago, which can interrogate each tumor ’s multi-omic and immune profile and identify its distinct molecular signature. This information can now be exploited in the clinic to provide precise, personalized therapeutic options. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 4, 2024 Category: Cancer & Oncology Authors: Elena Fountzilas, Apostolia-Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - March 1, 2024 Category: Cancer & Oncology Source Type: research
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis
Cancer-related pain is common, with an overall prevalence of 44.5 % and is experienced by 30.6 % of the patients as moderate to severe [1]. It diminishes quality of life by causing distress and affecting quality of sleep and physical, psychological, social and spiritual functioning [2,3]. Treatment of cancer-related pain can be challenging. It often consists of opioid-based pharmacotherapy [4–6]. Opioids have several gastrointestinal adverse effects, of which opioid-induced constipation (OIC) is the most common side effect with a reported prevalence ranging between 22 % and 81 % [7]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 29, 2024 Category: Cancer & Oncology Authors: K.R.J. Kistemaker, F. Sijani, D.J. Brinkman, A. de Graeff, G.L. Burchell, M.A.H. Steegers, L. van Zuylen Source Type: research
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Immunotherapy is effective in recurrent endometrial cancer (EC), particularly in patients harboring a deficit in the DNA mismatch repair system (dMMR) or with microsatellite instability-high (MSI-H) tumors. Currently, for patients with advanced disease in progression to platinum-based chemotherapy, dostarlimab or pembrolizumab used as a monotherapy are considered the standard of care for the dMMR/MSI-H subgroup. Additionally, pembrolizumab plus lenvatinib have been approved for both pMMR and dMMR/MSI-H patients. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 26, 2024 Category: Cancer & Oncology Authors: Michele Bartoletti, Marcella Montico, Domenica Lorusso, Roberta Mazzeo, Ana Oaknin, Lucia Musacchio, Giovanni Scambia, Fabio Puglisi, Sandro Pignata Tags: Systematic or Meta-analysis Studies Source Type: research
Cancer genetic counselling for hereditary breast cancer in the era of precision oncology
Breast cancer (BC) is the most frequent malignant tumor in females, with an estimated worldwide incidence of 297,790 new cases in 2023 [1]. Conversely, BC is a rare disease in men, accounting for less than 1 % of all BC. About 5–10 % of female BC are associated with pathogenetic (P)/likely pathogenetic (LP) variants in predisposing genes [2], while in around 16 % of all male BC cases, pathogenic BRCA variants are detected, with BRCA2 being the most prevalent [3]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 26, 2024 Category: Cancer & Oncology Authors: M. Pensabene, A. Calabrese, C. von Arx, R. Caputo, M. De Laurentiis Source Type: research
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions
Although the global incidence of CRC is expected to reach 3.2 million cases by 2040 [1], the age-standardized mortality rate worldwide has been declining over the last decades [2]. At diagnosis, 25 % of people will present with stage IV disease and nearly 60 % of patients with stage II-III CRC will develop post-operative recurrence [3]. The prognosis of patients with metastatic (m)CRC is heterogeneous and while the 5-year overall survival (OS) is generally around 12 %, certain subgroups may achieve 5-year OS rates of up to 40 % following resection of liver metastases [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 24, 2024 Category: Cancer & Oncology Authors: David Johnson, Cheng Ean Chee, Wesley Wong, Rachel C.T. Lam, Iain Bee Huat Tan, Brigette B.Y. Ma Tags: Anti-tumour Treatment Source Type: research
177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers
Prostate-specific membrane antigen (PSMA) is a zinc metalloenzyme belonging to the family of type II transmembrane protein; it is also known as Glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or Folate Hydrolase 1, and it is encoded by the FOLH1 (folate hydrolase 1) gene [1]. PSMA has been found to be expressed in several human tissues, such as prostate, nervous system, salivary glands, small intestine, and kidney, but its expression has been observed also in pathological conditions such as prostate cancer (PCa) and tumor-associated neovasculature [2 –5]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 17, 2024 Category: Cancer & Oncology Authors: Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi Source Type: research
Salivary gland carcinoma: Towards a more personalised approach
Salivary gland carcinomas (SGCs) are rare tumors accounting for less than 1% of all cancers with 21 histologically diverse subtypes [1]. The rarity of the disease presents a challenge for pathologists to establish the exact diagnosis and for clinicians to conduct large size randomized clinical trials. The incidence is variable worldwide with 1 case per 100 000 people in the US [2], around 720 new cases in UK every year [3], and 0.7/100000 person-years in men or 0.5/100000 person-years in women in France [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 12, 2024 Category: Cancer & Oncology Authors: Layal Rached, Khalil Saleh, Odile Casiraghi, Caroline Even Tags: Tumour Review Source Type: research
Theranostics Revolution in Prostate Cancer: Basics, Clinical Applications, Open Issues and Future Perspectives
In the last decade, the therapeutic algorithm of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized with the advent of various therapeutic strategies that significantly improved patients' outcomes. Systemic options that have demonstrated a survival benefit in this setting include chemotherapy (e.g., docetaxel and cabazitaxel), androgen receptor-signaling inhibitors (ARSI; e.g., enzalutamide and abiraterone acetate), and Poly (ADP-ribose) polymerase (PARP) inhibitors (e.g., olaparib, rucaparib, and talazoparib), either alone or combined with an ARSi, in a selected cohort of tumors harboring HRR,...
Source: Cancer Treatment Reviews - February 10, 2024 Category: Cancer & Oncology Authors: Matteo Bauckneht, Chiara Ciccarese, Riccardo Laudicella, Claudia Mosillo, Francesca D'Amico, Annunziato Anghelone, Alessandro Strusi, Viria Beccia, Sergio Bracarda, Giuseppe Fornarini, Giampaolo Tortora, Roberto Iacovelli Tags: Hot Topic Source Type: research
Preoperative chemotherapy in upfront resectable colorectal liver metastases: new elements for an old dilemma?
In early 2023, the European Society of Medical Oncology (ESMO) guidelines clarified the place of neoadjuvant chemotherapy (NAC) for resectable colorectal liver metastases (CRLM) [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - February 6, 2024 Category: Cancer & Oncology Authors: Lorenzo Bernardi, Raffaello Roesel, Davit L. Aghayan, Pietro E. Majno-Hurst, Sara De Dosso, Alessandra Cristaudi Tags: Controversy Source Type: research
High-dose chemotherapy for Ewing Sarcoma and Rhabdomyosarcoma: a systematic review by the Australia and New Zealand Sarcoma Association clinical practice guidelines working party
Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) are small round blue cell tumours that occur in children, adolescents and young adults (AYA) [1 –3]. In ES, the EWSR1-FLI1 fusion is identified in 85% of cases [1,4]. Small round cell sarcomas of bone and soft tissue where EWSR1-FLI1 fusion is not identified were previously collated with ES and termed the Ewing sarcoma family of tumours (ESFT) [1]. Molecular profiling has revealed fusions in cluding EWSR1–non-ETS fusions, CIC-rearrangements, and BCOR alterations by which these tumours are now classified and understood to confer different natural histories and treatment sens...
Source: Cancer Treatment Reviews - February 1, 2024 Category: Cancer & Oncology Authors: Ashika Ramamurthy, Elizabeth A Connolly, Jasmine Mar, Jeremy Lewin, Vivek A Bhadri, Marianne B Phillips, Mark Winstanley, Lisa M Orme, Peter Grimison, Joanna Connor, Smaro Lazarakis, Angela M Hong, Natacha Omer, Julie Cayrol Source Type: research
